newbaner

news

Great Bay Bio’s AI-enabled No-screening Cell Culture Media Development Platform Shaping the New Standards in Biopharmaceuticals

In the biopharmaceutical industry, the quality and performance of culture media have direct implications for cell line production efficiency, drug quality, and production costs. The traditional process of culture media development is often complicated and time-consuming. However, Great Bay Bio has fundamentally changed this scenario through its AI-enabled No-screening Cell Culture Media Development Platform. This advanced platform can not only develop optimal culture media within a month but also provide high-quality media additives in one single step. Most notably, it can increase protein expression levels by more than 50%.

Rapid Development

Traditional culture media development usually requires several months or even years, a time span that is unacceptable for urgently needed new drugs awaiting market release. Great Bay Bio’s platform, leveraging advanced algorithms and experimental procedures, can identify the optimal culture media within just a single month.

High-Quality Additives

In culture media, the quality of additives directly affects cell growth and protein expression. Great Bay Bio ‘s platform can provide high-quality additives in a single step, eliminating the need for additional screening and verification, thereby greatly simplifying the entire development process.

Increased Protein Expression Levels

In biopharmaceuticals, higher protein expression levels signify higher production efficiency and lower costs. This development platform from Great Bay Bio can increase protein expression levels by more than 50%, accelerating drug production and reducing production costs.

Application Prospects

Great Bay Bio’s AI-enabled No-screening Cell Culture Media Development Platform is applicable to multiple domains, including but not limited to antibody drugs, gene therapies, vaccine development, and the production of other high-end bioproducts. Its speed, efficiency, and high yield make it one of the most promising and revolutionary technologies in the industry.

Overall, Great Bay Bio’s AI-enabled No-screening Cell Culture Media Development Platform represents a significant breakthrough in the field of biopharmaceuticals. Its highly optimized and automated processes not only drastically shorten the time required for culture media development but also provide higher-quality additives, and most importantly, significantly increase protein expression levels. These advantages make this platform poised to become the new industry standard in biopharmaceuticals.

In a rapidly evolving and highly competitive market environment, this innovative platform undoubtedly brings lasting and profound impacts for the company itself, and even for the entire biopharmaceutical industry. As it is further implemented and validated in more application scenarios, there is every reason to believe that this technology will continue to drive the advancement of the biopharmaceutical industry, offering humanity better and more diverse treatment options.


Post time: Sep-01-2023